Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-88 in metastatic pancreatic cancer
NCT03512756Phase 3Terminated
- Sponsor
- Tyme Technologies
- Start
- Mar 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of racemetyrosine in pancreatic cancer (PC), sponsored by Tyme Technologies. Started Mar 2018; status: terminated.
02
Drugs
racemetyrosine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03512756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512756.